Published in Blood on September 01, 1974
Antibodies to actin in autoimmune haemolytic anaemia. BMC Vet Res (2010) 0.84
Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Haematologica (2015) 0.79
Development of complement therapeutics for inhibition of immune-mediated red cell destruction. Transfusion (2005) 0.78
Quantitation of C3 subcomponents on red cells coated with complement in vitro. J Clin Pathol (1980) 0.75
Erythrocyte autoimmune disorder: red cell antibodies and the human allogeneic rosette test. Clin Exp Immunol (1980) 0.75
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
Immune adherence by the fourth component of complement. Science (1969) 3.34
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion (1999) 2.66
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Misinterpretation and misapplication of p values in antibody identification: the lack of value of a p value. Transfusion (1997) 2.36
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Coombs-positive hemolytic anemia caused by penicillin administration. N Engl J Med (1966) 2.33
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
First year donation patterns predict long-term commitment for first-time donors. Vox Sang (2005) 2.18
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Anti-M causing delayed hemolytic transfusion reaction. Transfusion (1983) 2.04
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
More on p values in antibody identification. Transfusion (1998) 1.89
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol (1974) 1.74
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol (1968) 1.69
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol (1976) 1.67
Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med (1973) 1.63
Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion (2000) 1.61
Complement fixation by rheumatoid factor. J Clin Invest (1975) 1.60
Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion (2000) 1.58
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 1.58
Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway. J Exp Med (1976) 1.57
Cell cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation. Proc Natl Acad Sci U S A (1971) 1.53
Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol (1978) 1.53
Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine (Baltimore) (1971) 1.52
Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology (2003) 1.51
Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion (1997) 1.51
Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol (1981) 1.50
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Expression of a human cytomegalovirus receptor correlates with infectibility of cells. J Virol (1991) 1.48
Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol (1981) 1.44
Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol (1979) 1.44
Glomerular complement components in human glomerulonephritis. J Clin Invest (1974) 1.43
Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol (1980) 1.43
A comprehensive transfusion medicine curriculum for medical students. Transfusion Medicine Academic Award Group. Transfusion (1995) 1.42
Factors affecting the labor efficiency of hospital-based blood bank laboratories. Transfusion (1994) 1.39
An unusual Donath-Landsteiner antibody detectable at 37 degrees C by the antiglobulin test. Transfusion (1985) 1.38
Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging (1997) 1.36
Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology (1998) 1.34
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol (1986) 1.29
The subunit composition and sedimentation properties of human C1. J Immunol (1977) 1.27
Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol (1991) 1.27
The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein. J Virol (1990) 1.27
Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem (1989) 1.26
Inactivation of lysis of oncornaviruses by human serum. Virology (1976) 1.26
In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia. J Clin Invest (1969) 1.26
Identification of types of cells in human peripheral blood that bind C1q. J Immunol (1981) 1.25
A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol (1982) 1.24
Activation of C1r by proteolytic cleavage. J Immunol (1976) 1.23
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
First-time blood donors: demographic trends. Transfusion (2001) 1.23
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol (1979) 1.20
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett (2001) 1.20
International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report. Vox Sang (2011) 1.19
CR2 ligands modulate human B cell activation. J Immunol (1988) 1.18
The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol (1980) 1.18
Autoimmune hemolytic anemia with reticulocytopenia and erythroid marrow. N Engl J Med (1982) 1.18
Drug-induced immune hemolytic anemia. Am J Med (1975) 1.17
Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J Immunol (1982) 1.17
International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao report. Vox Sang (2009) 1.17
Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol (2001) 1.17
International Society of Blood Transfusion Committee on terminology for red cell surface antigens: Vancouver Report. Vox Sang (2003) 1.16
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol (2004) 1.15
Enzymatic activity of the second component of complement. Biochemistry (1975) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood (1986) 1.14
Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol (1983) 1.13
Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component. J Immunol (1974) 1.13
Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA (1985) 1.13
Blood group terminology 2004: from the International Society of Blood Transfusion committee on terminology for red cell surface antigens. Vox Sang (2004) 1.11
Immunologic reactions of humans to cephalosporins. Postgrad Med J (1971) 1.11
Demonstration and quantitation of activation of the first component of complement in human serum. J Exp Med (1978) 1.11
Drug-induced immune haemolytic anaemia. Clin Haematol (1980) 1.11
Specificity and immunoglobulin characteristics of autoantibodies in acquired hemolytic anemia. J Immunol (1971) 1.10
Formation and biologic role of polyoma virus-antibody complexes. A critical role for complement. J Exp Med (1974) 1.10
Complement in acute experimental malaria. I. Total hemolytic activity. Mil Med (1966) 1.08